Targeting the Androgen Receptor for Treatment of Prostate Cancer
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: closed (12 March 2020)
Special Issue Editor
Interests: prostate cancer, cell migration and invasion; 3D cell models; tumor microenvironment; prostate carcinoma-associated fibroblasts; cell cycle, androgen receptor non-genomic actions; growth factor receptors; signal transduction
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Prostate cancer (PC) is the most commonly diagnosed non-cutaneous tumor in men and the second leading cause of male cancer-related deaths. The role of androgens in prostate transformation and PC progression is well established, and molecular studies have extensively analyzed the mechanism of action of the androgen receptor (AR). These studies have made possible the synthesis of new drugs that modulate or inhibit the biological events induced by AR in PC cells. The long-term efficacy of these drugs, however, still remains unsatisfactory.
The AR is, indeed, also able to establish a cross-talk with other proteins, such as growth factor receptors (e.g., EGF-R, TrkA) or signaling effectors (e.g., FAK and proteins involved in integrin/adhesion pathways and Src and proteins involved in proliferation pathways), triggering invasiveness and cell cycle progression of PC cells.
Recently, it has been discovered that the AR is also expressed in tumor stroma and, in particular, in prostate carcinoma-associated fibroblasts, although the role of stromal AR in prostate tumorigenesis is still unclear.
This Special Issue aims to collect manuscripts on recent advances in the detection of new therapeutic targets in both epithelial and stromal compartments of PC and on innovative therapies for a more efficacious battle against PC.
Dr. Marzia Di Donato
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Prostate cancer
- Androgen Receptor
- Cross-talk
- Epithelial and mesenchymal cells
- Invasiveness
- Cell cycle
- New drugs
- New clinical protocols
- Metastasis
